Revenues from Pfizer’s Vaccine Business Increase

Article

According to a third-quarter earnings report, Pfizer’s vaccine business contributed nearly 14% to its total revenue.

Pfizer announced on Oct. 27, 2015 that compared with third-quarter earnings in 2014, revenues from its vaccine business increased by nearly 43%, and revenues specifically in the United States increased 78%, which the company said was driven by continued strong uptake of Prevnar 13 (pneumococcal 13-valent vaccine) among adults. Notably, global revenues in their oncology division increased by 54% operationally, which the company said was primarily driven by sales of their drug Ibrance (palbociclib)‎ for the treatment of advanced breast cancer.

Although the company reported an increase in R&D expenses-primarily as a result of increased spending associated with its anti-PD-L1 alliance with Merck KGaA-the R&D spend increase was partially offset by lower clinical trial spending for certain vaccine programs.

The company also recently completed its acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY conjugate vaccines-Nimenrix and Mencevax-for approximately $130 million, but the company said it did not expect the acquisition to significantly affect its 2015 financial performance.

Source: Pfizer
 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.